Onconetix, Inc. (NASDAQ:ONCO – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 20,300 shares, a drop of 94.6% from the September 30th total of 375,300 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 676,600 shares, the short-interest ratio is presently 0.0 days.
Onconetix Price Performance
Onconetix stock traded down $0.18 during midday trading on Friday, hitting $3.83. 17,886 shares of the stock were exchanged, compared to its average volume of 336,654. Onconetix has a fifty-two week low of $2.82 and a fifty-two week high of $21.40. The stock’s 50-day simple moving average is $5.11 and its 200 day simple moving average is $5.70.
Onconetix (NASDAQ:ONCO – Get Free Report) last announced its earnings results on Thursday, August 29th. The company reported ($9.20) earnings per share for the quarter. The business had revenue of $0.71 million for the quarter.
Institutional Inflows and Outflows
About Onconetix
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Further Reading
- Five stocks we like better than Onconetix
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is the NASDAQ Stock Exchange?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Investors Need to Know About Upcoming IPOs
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.